Exagen

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.

Exagen was established in 2002 and is headquartered in Vista, California.

Exagen headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Medical, Therapeutics, Genetics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $216.8B in funding across 672 round(s). With a team of 101-250 employees, Exagen is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Exagen, raised $7.0M. Discover more about their projects, partnerships, and impact on our platform.